Preface
The 13th Asian Congress of Dermatology (13th ADC 2024) was held in Shanghai from May 9 to 11, 2024. The quadrennial ADC Annual Meeting is the most extensive and representative academic event in the field of dermatology in Asia, with thousands of representatives from Asia, Europe and the United States attending the conference to share the latest research results in the field of dermatology in Asian countries. Professor Yan Zhao from Peking University People's Hospital published a study showing that spalzimab can rapidly and sustainably improve the clinical symptoms and severity of each affected area in patients with moderate to severe atopic dermatitis (AD).
1
Background:
Sprichbaimab is a novel humanized lgG4 monoclonal antibody targeting the interleukin-4 receptor α (lL-4Ra) subunit, blocking IL-4 and IL-13 signaling. Phase 3 trials showed that spalzimab significantly improved clinical symptoms, as evidenced by a reduction in overall disease severity.
2
Research Objectives
This post-hoc study was designed to evaluate the efficacy of spalzimab in different affected areas in patients with AD.
3
Research Methods:
Study design: This is a randomized, double-blind, placebo-controlled phase 3 trial of spalzimab in adult patients.
Study endpoints: The following post-hoc endpoints were analyzed in four different affected areas (head and neck, trunk, upper extremity, lower extremity): (1) Eczema Area and Severity Index (EASl) score, percent change from baseline to week 16; and (2) percent change in body surface area (%BSA) involved in AD from baseline to week 16.
Figure 1: Study design
4
Findings:
Baseline EASl score and %BSA were well balanced between the sprukzimab and placebo groups in different anatomical regions (Table 1).
Table 1: Baseline EASl scores and BSA percentages for different regions
At week 16, spalzimab showed consistent and similar reductions in EASl scores (Figure 2) and %BSA (Figure 3) in different affected areas compared with placebo.
Figure 2: Mean percent change in least squares (LS) in EASl scores from baseline to week 16 for different anatomical regions
Figure 3: Mean percent change in %BSA from baseline to week 16 in different anatomical regions
At the first visit at week 2, there was a significant improvement in EASl scores in all affected areas in the spruzbemab group compared with placebo, and a more significant improvement in EASI scores in the spruzbemab group at week 16 (Figure 2). In addition, a similar phenomenon was observed with %BSA (Figure 3).
conclusion
In adults with moderate to severe AD, spalzimab monotherapy improves the range and severity of clinical symptoms rapidly and sustainably, and the same response is observed in all anatomical regions.
Resources
1.Yan Zhao, et al. PO 015. ADC 2024.